Unity Clinical Research

Oklahoma City, Oklahoma 73118-2872

4 studies enrolling now · 26 studies all time

What they study most

Atopic Dermatitis, Chronic Spontaneous Urticaria (CSU), Dermatitis, Atopic, Eosinophilic Esophagitis, Hidradenitis Suppurativa, Moderate to Severe Opioid-use Disorder, Moderate-to-severe Atopic Dermatitis, Opioid Use Disorder, Plaque Psoriasis, Pruritus, Psoriasis, Type II Diabetes Mellitus

Studies at this site

• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa — Recruiting now
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus — Recruiting now
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Recruiting now
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Completed
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis — Completed
• Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users — Completed
• Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder — Completed
• A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial — Completed
• Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated — Completed
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa — Completed
• A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 — Stopped early
• B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis — Completed
• A Study of LY3471851 in Participants With Eczema — Completed
• A Study of LY3471851 in Participants With Psoriasis — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis — Stopped early
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) — Completed
• Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) — Completed
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis — Completed